Tumor necrosis factor-α and interleukin-1β mediate endothelial permeability induced by lipopolysaccharide-stimulated whole blood

Critical Care Medicine

Volumn 30, Issue 9, 2002, Pages 2063-2068

  Nooteboom, Arjan ^a   Van der Linden, Gees J ^a   Hendriks, Thijs ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytokines; Endothelium; Lipopolysaccharide; Monolayer; Permeability; Sepsis

Indexed keywords

ALBUMIN; DEXTRAN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; BLOOD; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; HOSPITAL LABORATORY; HUMAN; HUMAN CELL; MONOLAYER CULTURE; PLASMA; PRIORITY JOURNAL; RADIOIMMUNOASSAY; UNIVERSITY HOSPITAL;

EID: 0036743782     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200209000-00019     Document Type: Article

References (45)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
2. Jindal N, Hollenberg SM, Dellinger RP: Pharmacologic issues in the management of septic shock. Crit Care Clin 2000; 16:233-249
3. Balk PA: Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock. Crit Care Clin 2000; 16:337-352
4. Brun BC: The epidemiology of the systemic inflammatory response. Intensive Care Med 2000; 26 (Suppl 1):S64-S74
5. Baue AE, Durham R, Faist E: Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): Are we winning the battle? Shock 1998; 10:79-89
6. Woltmann A, Hamann L, Ulmer AJ, et al: Molecular mechanisms of sepsis. Langenbecks Arch Surg 1998; 383:2-10
7. Opal SM, Scannon PJ, Vincent JL, et al: Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999; 180:1584-1589
8. Casey LC, Balk PA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-778
9. Santos AA, Wilmore DW: The systemic inflammatory response: Perspective of human endotoxemia. Shock 1996; 6(Suppl 1): S50-S56
10. Ghosh S, Latimer RD, Gray BM, et al: Endotoxin-induced organ injury. Crit Care Med 1993; 21:S19-S24
11. Foca A. Berlinghieri MC, Barreca GS, et al: Kinetics of IL-8, MIP-1 alpha, TNF alpha, IL-1 beta, IL-1ra and IL-10 in human whole blood samples triggered by smooth and rough LPS. New Microbiol 1998; 21:123-130
12. Gardlund B, Sjolin J, Nilsson A, et al: Plasma levels of cytokines in primary septic shock in humans: Correlation with disease severity. J Infect Dis 1995; 172:296-301
13. Opal SM, Yu RL Jr: Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions. Drugs 1998; 55:497-508
14. Jansen MJ, Hendriks T, Hermsen R, et al: A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome. Cytokine 1998; 10:904-910
15. Deitch EA: Animal models of sepsis and shock: A review and lessons learned. Shock 1998; 9:1-11
16. Marshall JC: Clinical trials of mediator-directed therapy in sepsis: What have we learned? Intensive Care Med 2000; 26(Suppl 1):S75-S83
17. Bannerman DD, Goldblum SE: Direct effects of endotoxin on the endothelium: Barrier function and injury. Lab Invest 1999; 79:1181-1199
18. Redl H, Dinges HP, Buurman WA, et al: Expression of endothelial leukocyte adhesion molecule-1 in septic but not traumatic/hypovolemic shock in the baboon. Am J Pathol 1991; 139:461-466
19. Goldblum SE, Brann TW, Ding X, et al: Lipopolysaccharide (LPS)-binding protein and soluble CD14 function as accessory molecules for LPS-induced changes in endothelial barrier function, in vitro. J Clin Invest 1994; 93:692-702
20. von Asmuth EJ, Dentener MA, Bazil V, et al: Anti-CD14 antibodies reduce responses of cultured human endothelial cells to endotoxin. Immunology 1993; 80:78-83
21. Nooteboom A, Hendriks T, Otteholler I, et al: Permeability characteristics of human endothelial monolayers seeded on different extracellular matrix proteins. Mediators Inflamm 2001; 9:235-241
22. Burke GA, Keenan AK: Modulation of human endothelial cell permeability by combinations of the cytokines interleukin-1 alpha/beta, tumor necrosis factor-alpha and interferon-gamma. Immunopharmacology 1993; 25:1-9
23. Eggesbo JB, Hjermann I, Hostmark AT, et al: LPS induced release of IL-1 beta, IL-6, IL-8 and TNF-alpha in EDTA or heparin anticoagulated whole blood from persons with high or low levels of serum HDL. Cytokine 1996; 8:152-160
24. Desch CE, Kovach NL, Present W, et al: Production of human tumor necrosis factor from whole blood ex vivo. Lymphokine Res 1989; 8:141-146
25. Roumen RM, Hendriks T, van der Ven-Jongekrijg J, et al: Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993; 218:769-776
26. Jaffe EA, Nachman RL, Becker CG, et al: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52:2745-2756
27. McGill SN, Ahmed NA, Christou NV: Endothelial cells: Role in infection and inflammation. World J Surg 1998; 22:171-178
28. Volk T, Kox WJ: Endothelium function in sepsis. Inflamm Res 2000; 49:185-198
29. Dinarello CA: Proinfiammatory cytokines. Chest 2000; 118:503-508
30. Ulevitch RJ, Tobias PS: Recognition of Gramnegative bacteria and endotoxin by the innate immune system. Curr Opin Immunol 1999; 11:19-22
31. Villars F, Conrad V, Rouais F, et al: Ability of various inserts to promote endothelium cell culture for the establishment of coculture models. Cell Biol Toxicol 1996; 12:207-214
32. Pugin J, Ulevitch RJ, Tobias PS: A critical role for monocytes and CD14 in endotoxininduced endothelial cell activation. J Exp Med 1993; 178:2193-2200
33. Pugin J, Ulevitch RJ, Tobias PS: Tumor necrosis factor-alpha and interleukin-1 beta mediate human endothelial cell activation in blood at low endotoxin concentrations. J Inflamm 1995; 45:49-55
34. Lum H, Malik AB: Mechanisms of increased endothelial permeability. Can J Physiol Pharmacol 1996; 74:787-800
35. Dejana E, Valiron O, Navarro P, et al: Intercellular junctions in the endothelium and the control of vascular permeability. Ann N Y Acad Sci 1997; 811:36-43
36. Essler M, Staddon JM, Weber PC, et al: Cyclic AMP blocks bacterial lipopolysaccharide-induced myosin light chain phosphorylation in endothelial cells through inhibition of Rho/Rho kinase signaling. J Immunol 2000; 164:6543-6549
37. Hindmarsh EJ, Marks RM: Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells. J Immunol 1998; 160:6128-6136
38. Curtis TM, Rotundo RF, Vincent PA, et al: TNF-alpha-induced matrix Fn disruption and decreased endothelial integrity are independent of Fn proteolysis. Am J Physiol 1998; 275:L126-L138
39. Gyu KH, Young KG: Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2000; 269:401-405
40. Bannerman DD, Sathyamoorthy M, Goldblum SE: Bacterial lipopolysaccharide disrupts endothelial monolayer integrity and survival signaling events through caspase cleavage of adherens junction proteins. J Biol Chem 1998; 273:35371-35380
41. Messmer UK, Briner VA, Pfeilschifter J: Tumor necrosis factor-alpha and lipopolysaccharide induce apoptotic cell death in bovine glomerular endothelial cells. Kidney Int 1999; 55:2322-2337
42. Stefanec T: Endothelial apoptosis: Could it have a role in the pathogenesis and treatment of disease? Chest 2000; 117:841-854
43. Thijs LG, Hack CE: Time course of cytokine levels in sepsis. Intensive Care Med 1995; 21(Suppl 2):S258-S263
44. Wilson CS, Seatter SC, Rodriguez JL, et al: In vivo endotoxin tolerance: Impaired LPS-stimulated TNF release of monocytes from patients with sepsis, but not SIRS. J Surg Res 1997; 69:101-106
45. Kox WJ, Volk T, Kox SN, et al: Immunomodulatory therapies in sepsis. Intensive Care Med 2000; 26(Suppl 1):S124-S128